Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
luxdegalutamide + lutetium (177Lu) vipivotide tetraxetan
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous (for Lutetium (177Lu) Vipivotide Tetraxetan), Oral (for Luxdegalutamide)
01
Overview
This drug is a **combination therapy** composed of **luxdegalutamide**, a next-generation androgen receptor (AR) inhibitor, and **lutetium (177Lu) vipivotide tetraxetan (Pluvicto, 177Lu-PSMA-617)**, a radiopharmaceutical targeted against prostate-specific membrane antigen (PSMA). Lutetium (177Lu) vipivotide tetraxetan selectively binds to PSMA-expressing cells and delivers beta radiation via the lutetium-177 isotope, leading to DNA damage and cell death in PSMA-positive cancer cells[1][2][3][4][5]. Luxdegalutamide inhibits androgen receptor signaling, depriving prostate cancer cells of growth signals. This combination is under investigation for synergistic antitumor effects in metastatic castration-resistant prostate cancer (mCRPC) with high PSMA expression, with each component acting via different but complementary mechanisms.
- Other names
- Lutetium Lu 177 vipivotide tetraxetan177Lu-PSMA-617
02
Targets
AR (Adrenergic receptors)PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on luxdegalutamide + lutetium (177Lu) vipivotide tetraxetan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on luxdegalutamide + lutetium (177Lu) vipivotide tetraxetan.